Please assess the completion status of the following clinical trial:

Trial Title: Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Cohort 1(a \& b) Inclusion Criteria:~* Age 18 or older at the time of signed informed consent~* Not currently taking commercial Truvada for PrEP or any other investigational, oral medication for the purpose of HIV PrEP~* Willing and able to independently provide written informed consent~* Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test~Cohort 1(a \& b) Exclusion Criteria:~* Evidence of acute or chronic hepatitis B infection at the time of screening~* Other clinically significant acute or chronic medical condition, including severe infections requiring treatment such as tuberculosis, as determined by the study investigator~* Evidence of renal dysfunction (Creatinine Clearance \< 30 ml/min) at the time of screening; Use Cockroft-Gault equation: GFR = (140-Age in years) x (Weight in kg) / (72 x serum creatinine)~* History of bone fractures not explained by trauma~* Grade 3 laboratory abnormality on screening tests/assessments as defined by the DAIDS grading system~* Known allergy/sensitivity to the study drug or its components~* Experiencing decompensated cirrhosis (e.g., ascites, encephalopathy, etc.)~* Any other clinical condition or prior therapy that, in the opinion of the Principal Investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements~Cohort 2 Inclusion Criteria:~* Age 18 or older at the time of signed informed consent~* Willing and able to independently provide written informed consent~* Last viral load \< 20 copies/mL within the last four weeks of screening~* Must be on combination antiretroviral therapy that includes TAF/FTC for at least 6 months~* Undetectable viral load, as defined by \< 50 copies/ml, for at least 6 months~Cohort 2 Exclusion Criteria:~* Other clinically significant acute or chronic medical condition, including severe infections requiring treatment such as tuberculosis, as determined by the study investigator~* Evidence of renal dysfunction (Creatinine Clearance \< 30 ml/min) at the time of screening; Use Cockroft-Gault equation: GFR = (140-Age in years) x (Weight in kg) / (72 x serum creatinine)~* Grade 3 laboratory abnormality on screening tests/assessments as defined by the DAIDS grading system~* Experiencing decompensated cirrhosis (e.g., ascites, encephalopathy, etc.)~* Any other clinical condition or prior therapy that, in the opinion of the Principal Investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cohort 1a (Type: EXPERIMENTAL): Age 18 or older at the time of signed informed consent~* Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP~* Willing and able to independently provide written informed consent~* Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test
- Cohort 1b (Type: EXPERIMENTAL): Age 18 or older at the time of signed informed consent~* Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP~* Willing and able to independently provide written informed consent~* Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test
- Cohort 2 (Type: ACTIVE_COMPARATOR): * Age 18 or older at the time of signed informed consent~* Willing and able to independently provide written informed consent~* Last viral load \< 20 copies/mL within the last four weeks of screening~* Must be on combination antiretroviral therapy that includes TAF/FTC for at least 6 months~* Undetectable viral load, as defined by \< 50 copies/ml, for at least 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).